Global biotechnology company engages Almac’s newest IRT platform for the build of 15 new trials
Souderton, PA, USA – 11 February 2016 – Almac Clinical Technologies, part of the Almac Group, a global leader in technology for managing clinical trial patients and supplies has reached a major milestone by confirming that a global biotechnology company will be migrating to their newest generation Interactive Response Technology (IRT), IXRS® 3 platform for the upcoming build of 15 clinical studies across multiple therapeutic areas in early 2016.
Many of the leading research-focused healthcare organisations have reaped the time and cost saving benefits from migrating over to the IXRS 3 platform. Like many before them, this particular client partner will be provided with a customised platform that supports multiple integrations to meet specific needs throughout the each individual trial.
A tailored, intuitive, user-friendly interface will be employed to empower users, giving them a transparent view of data, reporting and information. This approach will help to mitigate the risk for error, as modifications can be made directly by the site, client or Almac.
Charlie Morris, VP, New Products & Services – Almac Clinical Technologies has commented: “We’ve worked closely with this client partner to design and implement key enhancements and integrations in the IXRS 3 platform to provide the right features to meet their needs, adapt to any protocol deviations, and match their experience. Our team of experts have worked to ensure a reduction in development time, while accelerating user/staff readiness.”
IXRS 3 was built to meet the market’s need for speed, adaptability, and mobile technology. The unique and customisable platform delivers faster, without compromising quality, allowing sponsors and CROs to effectively manage patient enrolment, drug assignment visits, and drug inventory throughout the lifecycle of a clinical trial. To learn more about Almac and IXRS 3, visit www.almacgroup.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
